Together our results suggest that targeting the TIP60/ΔNp63α axis may sensitize resistant SCC cancer to cisplatin and points to the potential utility of TIP60 inhibition as an adjunct therapy to overcome cisplatin resistance, offering a promising new avenue for therapeutic interventions in non-melanoma skin cancer. Here, KAT5 is linked to melanoma.